Published in Ann Intern Med on April 17, 2007
The Compartmental Biology of HIV in the Male Genital Tract | NCT02638493
Sex, Aging and Antiretroviral Pharmacokinetics | NCT00666055
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol (2010) 7.72
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr (2009) 5.48
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
From access to engagement: measuring retention in outpatient HIV clinical care. AIDS Patient Care STDS (2010) 3.03
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS (2011) 2.15
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One (2010) 1.88
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
Impact of a New York City Health Department initiative to expand HIV partner services outside STD clinics. Public Health Rep (2012) 1.76
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis (2011) 1.70
HIV prevention cost-effectiveness: a systematic review. BMC Public Health (2009) 1.58
The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55
Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology (2013) 1.54
Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49
Association of attitudes and beliefs towards antiretroviral therapy with HIV-seroprevalence in the general population of Kisumu, Kenya. PLoS One (2009) 1.45
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol (2011) 1.38
State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr (2012) 1.37
Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25
Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep (2011) 1.24
Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther (2010) 1.19
HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum. J Infect Dis (2011) 1.15
Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol (2012) 1.15
Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS (2012) 1.13
Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J Virol (2011) 1.11
AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses (2010) 1.07
Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J Clin Microbiol (2009) 1.04
HIV prevention by oral preexposure prophylaxis. Cold Spring Harb Perspect Med (2012) 1.03
Development and pilot testing of a standardized training program for a patient-mentoring intervention to increase adherence to outpatient HIV care. AIDS Patient Care STDS (2012) 1.03
Behavioral and biomedical combination strategies for HIV prevention. Cold Spring Harb Perspect Med (2012) 1.03
Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther (2012) 1.02
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother (2009) 1.01
Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine (2009) 1.01
Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial. AIDS Behav (2010) 0.99
Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res (2011) 0.98
Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. Biophys J (2009) 0.97
Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users. AIDS (2012) 0.97
Sexual risk behaviors among HIV-infected South African men and women with their partners in a primary care program: implications for couples-based prevention. AIDS Behav (2012) 0.95
Knowledge of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Denver, Colorado. AIDS Behav (2014) 0.94
HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. PLoS One (2011) 0.94
Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One (2013) 0.93
Barriers and facilitators to engagement of vulnerable populations in HIV primary care in New York City. J Acquir Immune Defic Syndr (2015) 0.93
Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.92
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother (2010) 0.91
Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020. AIDS Res Ther (2011) 0.91
Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. PLoS Med (2008) 0.90
Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc (2008) 0.90
Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy. J Virol (2010) 0.88
Wanted: a theoretical roadmap to research and practice across individual, interpersonal, and structural levels of analysis. AIDS Behav (2010) 0.86
Quantitative mass spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix-assisted laser desorption electrospray ionization. Anal Bioanal Chem (2014) 0.85
Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One (2013) 0.85
Sexual risk behaviors among HIV-infected South Indian couples in the HAART era: implications for reproductive health and HIV care delivery. AIDS Care (2011) 0.84
Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis. Curr Infect Dis Rep (2008) 0.83
Development of a culturally appropriate computer-delivered tailored Internet-based health literacy intervention for Spanish-dominant Hispanics living with HIV. BMC Med Inform Decis Mak (2014) 0.82
Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr (2010) 0.82
What do mathematical models tell us about the emergence and spread of drug-resistant HIV? Curr Opin HIV AIDS (2011) 0.82
Expanded Highly Active Antiretroviral Therapy Coverage - A Powerful Strategy to Curb Progression to AIDS, Death and New Infections. Eur Infect Dis (2009) 0.81
RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res Ther (2009) 0.81
The use of highly active retroviral therapy to reduce HIV incidence at the population level. CMAJ (2008) 0.80
How HIV treatment could result in effective prevention. Future Virol (2010) 0.80
A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy. BMC Infect Dis (2011) 0.79
Trends in condom use and risk behaviours after sexual exposure to HIV: a seven-year observational study. PLoS One (2014) 0.79
The use of preexposure treatments for HIV prophylaxis. HIV AIDS (Auckl) (2012) 0.78
The ART of preventing HIV. Nat Med (2011) 0.78
Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention. Pharm Pract (Granada) (2009) 0.78
A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. J Antimicrob Chemother (2016) 0.78
Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load. J Womens Health (Larchmt) (2013) 0.77
Factors associated with sexual risk behaviors with non-steady partners and lack of recent HIV testing among German men who have sex with men in steady relationships: results from a cross-sectional internet survey. BMC Public Health (2015) 0.77
Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. AIDS Res Hum Retroviruses (2015) 0.76
Acceptability of HIV/AIDS testing among pre-marital couples in Iran (2012). Niger Med J (2014) 0.75
Psychosocial determinants of HIV testing across stages of change in Spanish population: a cross-sectional national survey. BMC Public Health (2017) 0.75
Factors associated with unprotected anal sex with multiple non-steady partners in the past 12 months: results from the European Men-Who-Have-Sex-With-Men Internet Survey (EMIS 2010). BMC Public Health (2016) 0.75
Sexual behaviour of people living with HIV attending a tertiary care government hospital in Kathmandu, Nepal: a cross sectional study. BMC Res Notes (2015) 0.75
Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS One (2017) 0.75
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS (2005) 3.71
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 2.38
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30
In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother (2004) 2.27
A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis (2005) 2.26
HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A (2010) 2.25
Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother (2007) 2.22
Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science (2010) 2.19
Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr (2007) 2.17
A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One (2011) 2.06
How far will we need to go to reach HIV-infected people in rural South Africa? BMC Med (2007) 2.00
Infectious syphilis in high-income settings in the 21st century. Lancet Infect Dis (2008) 1.99
Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med (2009) 1.92
Linking population-level models with growing networks: a class of epidemic models. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 1.90
Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet (2009) 1.77
Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2013) 1.77
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis (2011) 1.70
Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.67
The reinfection threshold does not exist. J Theor Biol (2005) 1.66
Quantification of the role of discordant couples in driving incidence of HIV in sub-Saharan Africa. Lancet Infect Dis (2011) 1.64
Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? AIDS (2010) 1.57
Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr (2013) 1.56
Can influenza epidemics be prevented by voluntary vaccination? PLoS Comput Biol (2007) 1.55
The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55
"No one's at home and they won't pick up the phone": using the Internet and text messaging to enhance partner services in North Carolina. Sex Transm Dis (2014) 1.55
Assessing the impact of mass rape on the incidence of HIV in conflict-affected countries. AIDS (2010) 1.52
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr (2013) 1.50
Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci (2009) 1.48
Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr (2004) 1.45
Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther (2003) 1.42
Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog (2011) 1.42
Modelling an outbreak of an emerging pathogen. Nat Rev Microbiol (2007) 1.41
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One (2011) 1.40
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr (2006) 1.40
Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS (2011) 1.36
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc (2010) 1.35
Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis (2002) 1.33
Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect (2007) 1.32
Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit (2006) 1.28
Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS (2007) 1.26
Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother (2012) 1.23
Theory versus data: how to calculate R0? PLoS One (2007) 1.22
Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci Rep (2011) 1.22
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther (2003) 1.22
Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS (2013) 1.20
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic Syndr (2013) 1.20
A queueing model for chronic recurrent conditions under panel observation. Biometrics (2005) 1.18
The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos (2008) 1.17
Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos (2004) 1.15
HIV treatment, preexposure prophylaxis, and drug resistance: reconciling conflicting predictions from mathematical models. J Infect Dis (2013) 1.15
Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr (2010) 1.15
An attempt at a new analysis of the mortality caused by smallpox and of the advantages of inoculation to prevent it. 1766. Rev Med Virol (2004) 1.15
Mean-field analysis of an inductive reasoning game: application to influenza vaccination. Phys Rev E Stat Nonlin Soft Matter Phys (2007) 1.13
Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet (2013) 1.12
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS (2015) 1.10
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr (2004) 1.10
The challenge of defining standards of prevention in HIV prevention trials. J Med Ethics (2010) 1.09
Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS (2013) 1.08
Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs. PLoS One (2012) 1.08
Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol (2002) 1.08
Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr (2013) 1.07
Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J Infect Dis (2002) 1.07
High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.07
Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther (2006) 1.07
Calculating the potential for within-flight transmission of influenza A (H1N1). BMC Med (2009) 1.07
Modeling the potential impact of rectal microbicides to reduce hiv transmission in bathhouses. Math Biosci Eng (2006) 1.06
A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. Talanta (2009) 1.06
Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit (2012) 1.04
The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?". PLoS One (2007) 1.04
Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab Dispos (2008) 1.03
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. AIDS Behav (2015) 1.03
Costs of eliminating HIV in South Africa have been underestimated. Lancet (2010) 1.03
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr (2008) 1.02
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol (2012) 1.01
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother (2009) 1.01
Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit (2008) 1.01
A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.00
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol (2009) 1.00
Kaletra (lopinavir/ritonavir). Ann Pharmacother (2002) 0.99
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis (2009) 0.98
The importance of including dynamic social networks when modeling epidemics of airborne infections: does increasing complexity increase accuracy? BMC Med (2011) 0.97
Predicting the future of XDR tuberculosis. Lancet Infect Dis (2007) 0.95
Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opin Drug Metab Toxicol (2015) 0.95
Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Br J Clin Pharmacol (2006) 0.94
Potential public health impact of new tuberculosis vaccines. Emerg Infect Dis (2004) 0.94
Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS (2012) 0.94
Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy (2007) 0.93
Mapping antiretroviral drugs in tissue by IR-MALDESI MSI coupled to the Q Exactive and comparison with LC-MS/MS SRM assay. J Am Soc Mass Spectrom (2014) 0.93
An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. Anal Chim Acta (2008) 0.92
Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol (2002) 0.92
Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol (2010) 0.91